Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

Shares of NYSE OGN opened at $9.60 on Friday. Organon & Co. has a twelve month low of $9.18 and a twelve month high of $23.10. The company has a 50 day moving average of $13.46 and a 200 day ...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported first-quarter net income of $87 million. The Jersey City, New Jersey-based company said it had net ...

Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

This Women’s Month, Organon, dedicated to advancing women’s health at every stage of life, is raising awareness on the preventability and treatability of heart disease, urging women to take ...

Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon’s fourth quarter and full year 2024 results have not been finalized and are subject to ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future ...